Curia

Integrity Bio is a contract development and manufacturing organization specializing in the formulation and GMP filling of biologics. Established in 2003 by Dr. Byeong Chang, the company has successfully formulated over 150 biologics, including vaccines, antibodies, proteins, and peptides, for more than 75 clients. Integrity Bio focuses on hard-to-formulate products in both liquid and lyophilized forms. To address development challenges and enhance product lifecycles, the company has created proprietary solutions, including the LyoTip system, which facilitates easy reconstitution and injection of lyophilized products. Additionally, Integrity Bio has patented high concentration formulation technology that enables the conversion of lyophilized and liquid intravenous drugs into ready-to-use subcutaneous concentrations, catering to specific stability requirements.